West Pharmaceutical Services, Inc.

NYSE:WST

Medical - Instruments & Supplies

Healthcare
$404.02 +1.56%

+$5.04 today

Market cap
$28.14B
Beta
1.18
P/E (TTM)
43.6
EPS (TTM)
$7.54
Dividend yield
0.26%
52W Low $206.80High $336.82

Volume 0.59M

Average 0.85M

WST Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

West Pharmaceutical Services, Inc.NYSE: WST

Research & Development · Q2 FY2026 · quarter ended Jun 2026

Research & development grows, but more slowly than its trailing trend

Q2 FY2026 research & development of $19.7M rose 3.1% year over year, behind the +7.2% change in trailing-twelve-month research & development. Sequentially, it rose 24.7% from the prior quarter. Over 3 fiscal years it compounded at +8.3% a year.

Context

  • Research & development amounted to 2.4% of revenue in FY2025, unchanged from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +3.1% toward the trailing-twelve-month pace of +7.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$19.7M+24.7% QoQ
Last fiscal yearDec 2025
$74.3M+7.5% YoY
LTMJun 2026
$74.4M+7.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.1%——
1 year+7.5%——
3-year CAGR+8.3%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
74.3M USD
Year-over-year change
+7.5%
4-year CAGR
+8.9%

Research & Development vs competitors

How WST compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +7.2% is the highest of 4, against a peer median of +5.3%.
  • Research & development amounts to 2.2% of revenue for WST, versus a peer median of 6.1%.
WST Competitors
Research & Development for WST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ATRAptarGroup, Inc.LTM Jun 2026$325.34M USD——8.3%
ICUIICU Medical, Inc.LTM Jun 2026$86.32M USD-2.5%-2.0%4.0%
WSTWest Pharmaceutical Services, Inc.LTM Jun 2026$74.4M USD+7.2%+8.3%2.2%
STVNStevanato Group S.p.A.LTM Jun 2026€25.44M EUR+5.3%-10.8%2.1%
BLFSBioLife Solutions, Inc.LTM Mar 2026$8.14M USD+5.5%-20.0%8.2%
Peer median (excluding WST) —+5.3%-10.8%6.1%

Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.83B2.89B2.95B2.89B3.07B
Cost of Revenue1.66B1.75B1.82B1.89B1.97B
Gross Profit1.17B1.14B1.13B1B1.1B
Gross Margin41.5%39.5%38.4%34.6%35.9%
Research & Development52.8M58.5M68.4M69.1M74.3M
Selling, General & Admin361.9M316.9M353.4M338.5M393.1M
Operating Expenses414.7M375.4M421.8M407.6M485.9M
Depreciation & Amortization122.3M120.6M137.3M155.4M171.4M
EBITDA879.7M808.1M844.1M743.8M770.6M
EBITDA Margin31.1%28.0%28.6%25.7%25.1%
Operating Income758.7M763.5M710.9M594.6M617.4M
Operating Margin26.8%26.5%24.1%20.6%20.1%
Interest Income1M5.1M28M19.6M17.7M
Interest Expense8.5M7.6M8.8M2.9M600K
Other Income / Expenses10.3M(62.9M)4.8M5.6M(2.1M)
Income Before Tax769M700.6M715.7M600.2M615.3M
Pre-Tax Margin27.2%24.3%24.3%20.7%20.0%
Income Tax Expense107.2M114.7M122.3M107.5M121.6M
Net Income661.8M585.9M593.4M492.7M493.7M
Net Margin23.4%20.3%20.1%17.0%16.1%
EPS (Basic)8.907.887.996.756.83
EPS (Diluted)8.677.737.886.696.80
Weighted Avg Shares74.4M74.4M74.3M73M72.3M
Weighted Avg Shares (Diluted)76.3M75.8M75.3M73.7M72.7M

West Pharmaceutical Services, Inc.

NYSE:WST

Intrinsic Alpha fair value

Locked

Current Price

$404.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.